<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03456726</url>
  </required_header>
  <id_info>
    <org_study_id>E7438-J081-206</org_study_id>
    <nct_id>NCT03456726</nct_id>
  </id_info>
  <brief_title>Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation</brief_title>
  <official_title>A Phase 2 Study of Tazemetostat in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, Phase 2 study to assess the efficacy and safety of
      tazemetostat in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL)
      with EZH2 gene mutation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>From administration of the first dose of the study drug until disease progression, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent, or study termination (up to 30 months)</time_frame>
    <description>ORR is defined as the number of participants with a best overall response of complete response or partial response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From administration of the first dose of the study drug to the date of the first event (disease progression, death, etc.) (up to 30 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>From confirmation of the first response to the date of the first event (disease progression, death, etc.) (up to 30 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>From administration of the first dose of the study drug to confirmation of the first response (up to 30 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with any adverse event, as an assessment of safety</measure>
    <time_frame>From administration of the first dose of the study drug to 30 days after the last dose (up to 30 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>FL with EZH2 gene mutation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with follicular lymphoma (FL) with the EZH2 gene mutation will receive oral tazemetostat at a starting dose of 800 milligrams (mg) twice daily (1600 mg total daily dose) by continuous regimen, no less than 8 hours between doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DLBCL with EZH2 gene mutation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with diffuse large B-cell lymphoma (DLBCL) with the EZH2 gene mutation will receive oral tazemetostat at a starting dose of 800 mg twice daily (1600 mg total daily dose) by continuous regimen, no less than 8 hours between doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazemetostat</intervention_name>
    <description>Tazemetostat will be provided as a 200 mg oral tablet.</description>
    <arm_group_label>FL with EZH2 gene mutation</arm_group_label>
    <arm_group_label>DLBCL with EZH2 gene mutation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with histological diagnosis of B-cell non-Hodgkin's lymphoma (NHL) as
             follows:

               -  Cohort 1: Follicular lymphoma (FL)

               -  Cohort 2: Diffuse large B-cell lymphoma (including primary mediastinal B-cell
                  lymphoma and transformed FL)

          -  Participants who have confirmed EZH2 gene mutation of tumor in central laboratory

          -  Participants who have measurable disease

          -  Participants who had previous therapy with systemic chemotherapy and/or antibody
             therapy and for which no standard therapy exists

          -  Participants who had progressive disease or did not have response (complete response
             or partial response) in previous systemic therapy, or relapsed or progressed after
             previous systemic therapy

          -  Participants with Eastern Cooperative Oncology Group performance status of 0 to 1

          -  Participants with life expectancy of ≥3 months from starting study drug administration

          -  Participants with adequate renal, liver, and bone marrow function

          -  Male and female participants ≥20 years of age at the time of informed consent

          -  Participants who has provided written consent to participate in the study

        Exclusion Criteria:

          -  Participants with prior exposure to EZH2 inhibitor

          -  Participants with a history or a presence of central nerves invasion

          -  Participants with malignant pleural effusion, cardiac effusion, or ascites retention

          -  Participants with allogeneic stem cell transplantation

          -  Participants with medical need for the continued use of potent inhibitors of
             Cytochrome P450 3A (CYP3A)or potent inducer of CYP3A (including St. John's wort)

          -  Participants with significant cardiovascular impairment

             · Participants with prolongation of corrected QT interval using Fridericia's formula
             to &gt; 480 milliseconds (msec)

          -  Participants with venous thrombosis or pulmonary embolism within the last 3 months
             before starting study drug

          -  Participants with complications of hepatic cirrhosis, interstitial pneumonia or
             pulmonary fibrosis

          -  Participants with active infection requiring systemic therapy

          -  Women of childbearing potential or man of impregnate potential who don't agree that
             both the participant and his/her partner will use a medically effective method for
             contraception for periods from before informed consent to during the clinical study
             and 30 days later (for males 90 days later) from last administration of study drug

          -  Woman who are pregnant or breastfeeding

          -  Participants who were deemed as inappropriate to participate in the study by the
             investigator or sub-investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Customer Joy Department. EJ</last_name>
    <phone>81-3-3817-3700</phone>
    <email>CLNCL@hhc.eisai.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>1004 Eisai Trial Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1005 Eisai Trial Site</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1002 Eisai Trial Site</name>
      <address>
        <city>Isehara</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1006 Eisai Trial Site</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1001 Eisai Trial Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1003 Eisai Trial Site</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2018</study_first_submitted>
  <study_first_submitted_qc>March 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EZH2 gene mutation</keyword>
  <keyword>Tazemetostat</keyword>
  <keyword>Diffuse large B-cell lymphoma</keyword>
  <keyword>Follicular lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

